USPTO Examiner GRASMEDER SARAH DYMPNA - Art Unit 3783

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18618887ACTUATING MECHANISM FOR FLUID DISPLACEMENT AND PRESSURIZING DEVICESMarch 2024April 2025Allow1340NoNo
18488354Injector DeviceOctober 2023August 2024Allow1010NoNo
18199532Auto Injector With Improved FunctionalityMay 2023May 2024Allow1210NoNo
17743959Rotary Motor Based Transdermal Injection DeviceMay 2022March 2025Allow3410NoNo
17716603BOTULINUM TOXIN PREFILLED SYRINGE SYSTEMApril 2022June 2025Abandon3810NoNo
17761013Passive Safety Device, Injection Device Comprising the Same, and Method for Manufacturing Said Injection DeviceMarch 2022August 2024Allow2930YesNo
17588592INTRAVASCULAR CATHETER AND METHOD OF USEJanuary 2022February 2024Abandon2540YesNo
17542096Passive Dilation in Catheter Insertion SystemsDecember 2021May 2025Allow4151NoYes
17533859PEN NEEDLE EXCHANGE SYSTEMNovember 2021May 2025Abandon4110NoNo
17527452METHOD OF ROBOTICALLY PERFORMING A NEUROVASCULAR PROCEDURENovember 2021October 2024Allow3530YesNo
17602383INFUSION HEAD WITH CONTROLLED RELEASE OF SECONDARY DRUGOctober 2021March 2025Abandon4110NoNo
17488744ACTUATING MECHANISM FOR FLUID DISPLACEMENT AND PRESSURIZING DEVICESSeptember 2021March 2024Allow2910YesNo
17447751Multi-Function SyringeSeptember 2021November 2023Abandon2601NoNo
17464258INTRAVASCULAR OXYGENATION SYSTEM AND METHODSeptember 2021March 2025Abandon4221NoNo
17462495INFUSION PUMP WITH TOGGLING CAPABILITYAugust 2021March 2025Allow4310YesNo
17297513SYRINGE SAFETY CAP AND SAFETY SYRINGE INCLUDING THE SAMEMay 2021October 2023Allow2910YesNo
17313901Enhanced Guide Wire Advancement LengthMay 2021July 2024Allow3920YesNo
17284554SealApril 2021January 2024Abandon3310NoNo
17210685Alopecia Repair SystemMarch 2021April 2025Abandon4810NoNo
17200566Guidewire-Management Devices and Methods ThereofMarch 2021April 2024Allow3721YesNo
17200630Guidewire-Management Devices and Methods ThereofMarch 2021September 2024Allow4231YesNo
17190001GUIDE WIRE INTRODUCERMarch 2021October 2024Allow4330NoNo
17187536Catheter with Optic Shape Sensing CapabilitiesFebruary 2021October 2024Allow4440YesNo
17262676InjectorJanuary 2021June 2025Allow5350NoNo
17151385INFUSION DEVICEJanuary 2021November 2023Allow3410YesNo
17253667TWO-CHAMBER TYPE COMBINED CONTAINER-SYRINGEDecember 2020June 2025Allow5450NoNo
17102958Rotary Motor Based Transdermal Injection DeviceNovember 2020May 2024Allow4200NoNo
17056702NEEDLE GUARDNovember 2020April 2025Allow5360YesNo
17056068NEEDLELESS PAIN-FREE INJECTION DEVICENovember 2020September 2023Allow3420NoNo
17054478DEVICE AND METHOD FOR INJECTING LIQUID DRUG INTO NASAL CAVITY AND PARANASAL SINUSESNovember 2020October 2023Abandon3510NoNo
17054377MALE CONNECTING DEVICE FOR MEDICAL USENovember 2020May 2024Allow4220NoNo
17053993CONNECTING STRUCTURE FOR MEDICAL USENovember 2020September 2023Allow3400NoNo
17086498ELECTROPORATION PROBENovember 2020October 2023Abandon3510NoNo
17085341DEVICEOctober 2020March 2024Abandon4110NoNo
17250010SYSTEMS AND METHODS FOR SYRINGE HANDLINGOctober 2020September 2024Allow4710YesNo
17079320Guidewire-Management Devices and Methods ThereofOctober 2020August 2024Allow4631NoNo
17049743IMPLANTABLE ULTRASOUND CONDUCTING AND DRUG DELIVERING APPARATUSOctober 2020March 2025Abandon5320NoNo
17077536INSUFFLATION DEVICE AND METHOD OF CONTROLLING INSUFFLATION DEVICEOctober 2020March 2025Abandon5220NoNo
16979636Dose Control Device for Injectable-Drug Delivery DevicesOctober 2020April 2024Allow4320YesNo
17044962ELONGATED FUNCTIONAL SYSTEM CONFIGURED TO BE ADVANCED IN THE LUMEN OF A PIPE, A DUCT OR A TUBEOctober 2020May 2025Abandon5640NoNo
17043991Auto Injector With Improved FunctionalitySeptember 2020April 2023Allow3010YesNo
17031511INFUSION CATHETER AND METHODS OF USESeptember 2020June 2024Allow4520YesNo
17040439DEVICE FOR ADMINISTERING A FLUIDSeptember 2020April 2024Allow4320NoNo
17021773MRI SURGICAL SYSTEMS INCLUDING MRI-COMPATIBLE SURGICAL CANNULAS FOR TRANSFERRING A SUBSTANCE TO AND/OR FROM A PATIENTSeptember 2020January 2025Abandon5230NoNo
16968954Injector DeviceAugust 2020July 2023Allow3520YesNo
16966500PREFILLED SYRINGE AND METHOD OF STERILIZING A PREFILLED SYRINGEJuly 2020May 2025Allow5721NoNo
16601169FLUID DELIVERY DEVICE AND BONE SCREWOctober 2019January 2025Allow6031YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GRASMEDER, SARAH DYMPNA.

Strategic Value of Filing an Appeal

Total Appeal Filings
1
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
1
(100.0%)
Filing Benefit Percentile
8.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner GRASMEDER, SARAH DYMPNA - Prosecution Strategy Guide

Executive Summary

Examiner GRASMEDER, SARAH DYMPNA works in Art Unit 3783 and has examined 46 patent applications in our dataset. With an allowance rate of 67.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.

Allowance Patterns

Examiner GRASMEDER, SARAH DYMPNA's allowance rate of 67.4% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by GRASMEDER, SARAH DYMPNA receive 2.07 office actions before reaching final disposition. This places the examiner in the 68% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by GRASMEDER, SARAH DYMPNA is 41 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +44.4% benefit to allowance rate for applications examined by GRASMEDER, SARAH DYMPNA. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 29.4% of applications are subsequently allowed. This success rate is in the 47% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 21.1% of cases where such amendments are filed. This entry rate is in the 19% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 99% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 99% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 85% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 43% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 42% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.